| References |
Top |
| REF 1 |
Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-beta and promotes tumor invasion and angiogenesis. Genes Dev. 2000 Jan 15;14(2):163-76.
|
| REF 2 |
Using an in situ proximity ligation assay to systematically profile endogenous protein-protein interactions in a pathway network. J Proteome Res. 2014 Dec 5;13(12):5339-46.
|
| REF 3 |
Architecture of the human interactome defines protein communities and disease networks. Nature. 2017 May 25;545(7655):505-509.
|
| REF 4 |
Structural insight into the complex formation of latent matrix metalloproteinase 2 with tissue inhibitor of metalloproteinase 2. Proc Natl Acad Sci U S A. 2002 May 28;99(11):7414-9.
|
| REF 5 |
Utilization of a novel recombinant myoglobin fusion protein expression system to characterize the tissue inhibitor of metalloproteinase (TIMP)-4 and TIMP-2 C-terminal domain and tails by mutagenesis. The importance of acidic residues in binding the MMP-2 hemopexin C-domain. J Biol Chem. 2002 Dec 13;277(50):48696-707.
|
| REF 6 |
Interaction of matrix metalloproteinases-2 and -9 with pregnancy zone protein and alpha2-macroglobulin. Arch Biochem Biophys. 1997 Nov 1;347(1):62-8.
|
| REF 7 |
Human tissue inhibitor of metalloproteinases 3 interacts with both the N- and C-terminal domains of gelatinases A and B. Regulation by polyanions. J Biol Chem. 1999 Apr 16;274(16):10846-51.
|
